BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 18339640)

  • 1. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
    Ikonomovic MD; Abrahamson EE; Price JC; Hamilton RL; Mathis CA; Paljug WR; Debnath ML; Cohen AD; Mizukami K; DeKosky ST; Lopez OL; Klunk WE
    Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous.
    Abrahamson EE; Kofler JK; Becker CR; Price JC; Newell KL; Ghetti B; Murrell JR; McLean CA; Lopez OL; Mathis CA; Klunk WE; Villemagne VL; Ikonomovic MD
    Brain; 2022 Jun; 145(6):2161-2176. PubMed ID: 34918018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
    Chen CD; Joseph-Mathurin N; Sinha N; Zhou A; Li Y; Friedrichsen K; McCullough A; Franklin EE; Hornbeck R; Gordon B; Sharma V; Cruchaga C; Goate A; Karch C; McDade E; Xiong C; Bateman RJ; Ghetti B; Ringman JM; Chhatwal J; Masters CL; McLean C; Lashley T; Su Y; Koeppe R; Jack C; Klunk WE; Morris JC; Perrin RJ; Cairns NJ; Benzinger TLS
    Acta Neuropathol; 2021 Oct; 142(4):689-706. PubMed ID: 34319442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.
    Rosen RF; Ciliax BJ; Wingo TS; Gearing M; Dooyema J; Lah JJ; Ghiso JA; LeVine H; Walker LC
    Acta Neuropathol; 2010 Feb; 119(2):221-33. PubMed ID: 19690877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
    Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
    Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer's disease brains: Implications for in-vivo diagnostics.
    den Haan J; Morrema THJ; Rozemuller AJ; Bouwman FH; Hoozemans JJM
    Acta Neuropathol Commun; 2018 Aug; 6(1):75. PubMed ID: 30092839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.
    Shin J; Lee SY; Kim SH; Kim YB; Cho SJ
    Neuroimage; 2008 Nov; 43(2):236-44. PubMed ID: 18694837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.
    Burack MA; Hartlein J; Flores HP; Taylor-Reinwald L; Perlmutter JS; Cairns NJ
    Neurology; 2010 Jan; 74(1):77-84. PubMed ID: 20038776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.
    Ni R; Gillberg PG; Bergfors A; Marutle A; Nordberg A
    Brain; 2013 Jul; 136(Pt 7):2217-27. PubMed ID: 23757761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
    Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
    J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
    Lowe VJ; Lundt ES; Albertson SM; Przybelski SA; Senjem ML; Parisi JE; Kantarci K; Boeve B; Jones DT; Knopman D; Jack CR; Dickson DW; Petersen RC; Murray ME
    Alzheimers Dement; 2019 Jul; 15(7):927-939. PubMed ID: 31175025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.
    Verhoeff NP; Wilson AA; Takeshita S; Trop L; Hussey D; Singh K; Kung HF; Kung MP; Houle S
    Am J Geriatr Psychiatry; 2004; 12(6):584-95. PubMed ID: 15545326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.